Group items tagged

A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.

A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).

Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.